AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21383275 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based care group (preventive medications administered by school nurses)
Number of subjects: 530
Study 21383275 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based care group
Number of subjects: 530
Study 21383275 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based care group (for children with smoke exposure)
Number of subjects: 530
Study 19698035 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal-epidural anesthesia plus intravenous patient-controlled anesthesia with tramadol
Number of subjects: 180
Study 19698035 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia (propofol induction, maintenance with sevoflurane) plus intravenous patient-controlled anesthesia with tramadol
Number of subjects: 180
Study 17904943 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy milk (720 mL daily)
Number of subjects: 14
Study 17904943 — intervention group
Group type: COMPARATOR
Intervention: Skim milk (720 mL daily)
Number of subjects: 14
Study 15779842 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 35
Study 15779842 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 35
Study 11736773 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.125% (group R)
Number of subjects: 32
Study 11736773 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine 0.125% (group B)
Number of subjects: 32
Study 7948760 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct Fluorescent Antibody (DFA) testing
Number of subjects: 384
Study 7948760 — intervention group
Group type: COMPARATOR
Intervention: Methenamine Silver Staining (MSS)
Number of subjects: 384
Study 7948760 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined use of DFA and MSS
Number of subjects: 384
Study 3252245 — intervention group
Group type: EXPERIMENTAL
Intervention: Tryptophan deficient amino acid mixture
Number of subjects: 0
Study 3252245 — intervention group
Group type: COMPARATOR
Intervention: Nutritionally balanced amino acid mixture
Number of subjects: 0
Study 29973252 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone-delivered cognitive behavioral therapy (CBT) components including self-monitoring, cognitive restructuring, behavioral activation, assertion training, and problem solving.
Number of subjects: 0
Study 27468953 — intervention group
Group type: EXPERIMENTAL
Intervention: Men
Number of subjects: 819
Study 27468953 — intervention group
Group type: COMPARATOR
Intervention: Women
Number of subjects: 819
Study 27468953 — intervention group
Group type: COMPARATOR
Intervention: Men and Women
Number of subjects: 819
Study 26852497 — intervention group
Group type: EXPERIMENTAL
Intervention: System of early diagnosis and non-pharmacological primary prevention including climatotherapeutic and physiotherapeutic methods, personalized dietary therapy, hypoxic-hypercapnic factors, and educational programs.
Number of subjects: 310
Study 26852497 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 310
Study 23546935 — intervention group
Group type: EXPERIMENTAL
Intervention: Delamanid-containing regimens (treatment group)
Number of subjects: 38
Study 23546935 — intervention group
Group type: COMPARATOR
Intervention: Placebo-containing regimens (control group)
Number of subjects: 38
Study 21722684 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 μg CHO hepatitis B vaccine
Number of subjects: 642
Study 21722684 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 μg CHO hepatitis B vaccine
Number of subjects: 642
Study 21722684 — intervention group
Group type: COMPARATOR
Intervention: Comparison of 10 μg and 20 μg groups
Number of subjects: 642
Study 18307589 — intervention group
Group type: EXPERIMENTAL
Intervention: peg-IFN alpha 2b plus ribavirin
Number of subjects: 383
Study 18307589 — intervention group
Group type: COMPARATOR
Intervention: IFN alpha-2b plus ribavirin
Number of subjects: 383
Study 18307589 — intervention group
Group type: EXPERIMENTAL
Intervention: peg-IFN alpha-2b
Number of subjects: 383
Study 18307589 — intervention group
Group type: EXPERIMENTAL
Intervention: NNRTI-containing antiretroviral regimens
Number of subjects: 383
Study 18307589 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe weight loss
Number of subjects: 383
Study 18307589 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss >5%
Number of subjects: 383
Study 16689009 — intervention group
Group type: EXPERIMENTAL
Intervention: Jinghua Weikang Capsule (JWC), 160 mg 3 times per day, orally before meals for 4 weeks
Number of subjects: 200
Study 16689009 — intervention group
Group type: COMPARATOR
Intervention: famotidine 20 mg twice per day, orally before meals for 4 weeks
Number of subjects: 200
Study 12673785 — intervention group
Group type: EXPERIMENTAL
Intervention: PPARγ2 Ala homozygotes (n = 6)
Number of subjects: 284
Study 10946310 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human IL-10 (25 microg/kg)
Number of subjects: 16
Study 10946310 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 9056005 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin 300 mg intravenously (i.v.) every 8 hours (q8h)
Number of subjects: 12
Study 9056005 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin 300 mg intravenously (i.v.) every 12 hours (q12h)
Number of subjects: 12
Study 9056005 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin 300 mg orally (p.o.) every 8 hours (q8h)
Number of subjects: 12
Study 9056005 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin 300 mg orally (p.o.) every 12 hours (q12h)
Number of subjects: 12
Study 8285777 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole (40 mg/day/1.73 m2 surface area)
Number of subjects: 32
Study 8285777 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine (20 mg/kg/day)
Number of subjects: 32
Study 2957052 — intervention group
Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate (MPA) 1 g daily
Number of subjects: 29
Study 2957052 — intervention group
Group type: EXPERIMENTAL
Intervention: Provera (100- and 200-mg tablets)
Number of subjects: 29
Study 2957052 — intervention group
Group type: COMPARATOR
Intervention: Farlutal (500-mg tablets)
Number of subjects: 29
Study 30314281 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatty fish (herring/mackerel)
Number of subjects: 232
Study 30314281 — intervention group
Group type: COMPARATOR
Intervention: Meat (chicken/lamb/beef)
Number of subjects: 232
Study 27017490 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended EI (3-year EI)
Number of subjects: 160
Study 27017490 — intervention group
Group type: COMPARATOR
Intervention: Step-down psychiatric care (SC, 2-year EI)
Number of subjects: 160
Study 26075288 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined exercise
Number of subjects: 20
Study 26075288 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study 23640971 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban 5 mg twice daily
Number of subjects: 18201
Study 23640971 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 18201
Study 20739792 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole for 1 week (group A, n=58)
Number of subjects: 120
Study 20739792 — intervention group
Group type: COMPARATOR
Intervention: Albendazole for 4 weeks (group B, n=62)
Number of subjects: 120
Study 17634183 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous budesonide (400 microg twice daily for 1 month, 200 microg twice daily for months 2‐6, 100 microg twice daily for months 7‐18)
Number of subjects: 176
Study 17634183 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide as needed (identical treatment to group 1 during months 1‐6, then budesonide for exacerbations as needed for months 7‐18)
Number of subjects: 176
Study 17634183 — intervention group
Group type: COMPARATOR
Intervention: Disodium cromoglycate (DSCG) 10 mg three times daily for months 1‐18
Number of subjects: 176
Study 16420563 — intervention group
Group type: EXPERIMENTAL
Intervention: Pro12Ala polymorphism in the peroxisome proliferator activated-receptor gamma gene
Number of subjects: 2615
Study 16420563 — intervention group
Group type: EXPERIMENTAL
Intervention: Thr164Ile polymorphism in the beta-2 adrenergic receptor gene
Number of subjects: 2615
Study 16420563 — intervention group
Group type: EXPERIMENTAL
Intervention: Ala23Thr polymorphism in the eotaxin gene
Number of subjects: 2615
Study 14693301 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin 20 mg/d
Number of subjects: 838
Study 14693301 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin 40 mg/d
Number of subjects: 838
Study 14693301 — intervention group
Group type: COMPARATOR
Intervention: Fluvastatin 20 mg/d
Number of subjects: 838
Study 14693301 — intervention group
Group type: COMPARATOR
Intervention: Fluvastatin 40 mg/d
Number of subjects: 838
Study 14693301 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin (both dosages)
Number of subjects: 838
Study 11044537 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalteparin 5000 IU daily (prophylactic dose)
Number of subjects: 48
Study 11044537 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjusted-weight dalteparin therapeutic dose of 100 IU/kg twice daily
Number of subjects: 48
Study 8793697 — intervention group
Group type: EXPERIMENTAL
Intervention: History of treated hypertension
Number of subjects: 11483
Study 8793697 — intervention group
Group type: COMPARATOR
Intervention: No history of treated hypertension
Number of subjects: 11483
Study 8227722 — intervention group
Group type: EXPERIMENTAL
Intervention: Regional anticoagulation
Number of subjects: 64
Study 8227722 — intervention group
Group type: COMPARATOR
Intervention: Low dose pre‐filter heparin
Number of subjects: 64
Study 8227722 — intervention group
Group type: COMPARATOR
Intervention: No anticoagulation
Number of subjects: 64
Study 8227722 — intervention group
Group type: EXPERIMENTAL
Intervention: CVVHD without anticoagulation
Number of subjects: 64
Study 3955779 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone 2g daily (1st trial)
Number of subjects: 62
Study 3955779 — intervention group
Group type: COMPARATOR
Intervention: Cefotaxime 2g twice daily (1st trial)
Number of subjects: 62
Study 3955779 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone 1g once daily (2nd trial)
Number of subjects: 62
Study 3955779 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone 2g single daily (1st trial)
Number of subjects: 62
Study 3955779 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone and Cefotaxime
Number of subjects: 62
Study 30078506 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized adjuvant treatment based on a molecular‐integrated risk profile
Number of subjects: 50
Study 30078506 — intervention group
Group type: COMPARATOR
Intervention: Standard adjuvant treatment; vaginal brachytherapy
Number of subjects: 50
Study 26724694 — intervention group
Group type: EXPERIMENTAL
Intervention: Measurement-based antidepressant management
Number of subjects: 0
Study 24853781 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive medication
Number of subjects: 169
Study 24853781 — intervention group
Group type: COMPARATOR
Intervention: No antihypertensive medication
Number of subjects: 169
Study 22153787 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim (TMP)
Number of subjects: 10
Study 22153787 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 22153787 — intervention group
Group type: EXPERIMENTAL
Intervention: TMP
Number of subjects: 10
Study 20932395 — intervention group
Group type: EXPERIMENTAL
Intervention: Preformed metal crowns (Hall technique)
Number of subjects: 48
Study 18594928 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodopovidone pleurodesis via conventional (32F) chest tube (group 1)
Number of subjects: 41
Study 18594928 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodopovidone pleurodesis via small-bore catheter (group 2)
Number of subjects: 41
Study 18594928 — intervention group
Group type: COMPARATOR
Intervention: Overall response rates for both groups
Number of subjects: 41
Study 18594928 — intervention group
Group type: COMPARATOR
Intervention: Complication rates for both groups
Number of subjects: 41
Study 16288147 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal education program based on the temperament theory
Number of subjects: 94
Study 12902100 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous amiodarone
Number of subjects: 30
Study 12902100 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 10578215 — intervention group
Group type: EXPERIMENTAL
Intervention: Advice to eat more fish (2 portions of fatty fish each week)
Number of subjects: 2033
Study 8678389 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 micrograms of rgp 120 in MF59
Number of subjects: 49
Study 8678389 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 micrograms of rgp 120 in MF59
Number of subjects: 49
Study 8678389 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 micrograms of rgp 120 in MF59 plus 50 micrograms of MTP-PE
Number of subjects: 49
Study 8678389 — intervention group
Group type: COMPARATOR
Intervention: MF59 alone
Number of subjects: 49
Study 8678389 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 monthly injections of 50 micrograms of rgp 120 in MF59
Number of subjects: 49
Study 8678389 — intervention group
Group type: EXPERIMENTAL
Intervention: gp120
Number of subjects: 49
Study 8678389 — intervention group
Group type: EXPERIMENTAL
Intervention: CD8+ cytotoxic T-lymphocyte activity
Number of subjects: 49
Study 1878267 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 minute booking intervals (experimental sessions)
Number of subjects: 16
Study 1878267 — intervention group
Group type: COMPARATOR
Intervention: Usual booking intervals of 7.5 to 5.0 minutes (control sessions)
Number of subjects: 16
Study 6364329 — intervention group
Group type: EXPERIMENTAL
Intervention: 2000 mg metronidazole as a single dose on the first and third days
Number of subjects: 63
Study 6364329 — intervention group
Group type: EXPERIMENTAL
Intervention: 2000 mg metronidazole as a single dose
Number of subjects: 63
Study 6364329 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg metronidazole 2 times daily for 7 days
Number of subjects: 63
Study 30892292 — intervention group
Group type: COMPARATOR
Intervention: Pink- neck implant
Number of subjects: 40
Study 30892292 — intervention group
Group type: COMPARATOR
Intervention: Pink abutment
Number of subjects: 40
Study 29508120 — intervention group
Group type: EXPERIMENTAL
Intervention: Responses from 2011 cohort (185 participants)
Number of subjects: 444
Study 29508120 — intervention group
Group type: COMPARATOR
Intervention: Responses from 2000 cohort (259 participants)
Number of subjects: 444
Study 27050869 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone (100 mg testosterone gel daily for 6 months)
Number of subjects: 64
Study 27050869 — intervention group
Group type: COMPARATOR
Intervention: Placebo (placebo gel daily for 6 months)
Number of subjects: 64
Study 25064150 — intervention group
Group type: EXPERIMENTAL
Intervention: X‐STOP device implantation
Number of subjects: 542
Study 25064150 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 542
Study 21752862 — intervention group
Group type: EXPERIMENTAL
Intervention: Volitional planning and self‐efficacy intervention
Number of subjects: 205
Study 21752862 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational skin cancer prevention approach
Number of subjects: 205
Study 21752862 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 205
Study 19580469 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate (5 mg/day)
Number of subjects: 49
Study 19580469 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 18081899 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrophilic acrylic IOL (BL27)
Number of subjects: 120
Study 18081899 — intervention group
Group type: COMPARATOR
Intervention: Hydrophobic acrylic IOL (SA60AT)
Number of subjects: 120
Study 16156113 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl HCl PCTS applied to upper outer arm
Number of subjects: 0
Study 16156113 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl HCl PCTS applied to chest
Number of subjects: 0
Study 16156113 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl HCl PCTS applied to lower inner arm
Number of subjects: 0
Study 16156113 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl HCl 40 microg via PCTS
Number of subjects: 0
Study 16156113 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl HCl 120 microg intravenously
Number of subjects: 0
Study 12022894 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole for 5 days
Number of subjects: 12
Study 12022894 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 9935021 — intervention group
Group type: EXPERIMENTAL
Intervention: Nuclear magnetic resonance (NMR) imaging
Number of subjects: 13
Study 7578653 — intervention group
Group type: EXPERIMENTAL
Intervention: Tryptophan depletion followed by yohimbine 0.4 mg/kg IV
Number of subjects: 11
Study 7578653 — intervention group
Group type: COMPARATOR
Intervention: Yohimbine 0.4 mg/kg IV alone
Number of subjects: 11
Study 7578653 — intervention group
Group type: COMPARATOR
Intervention: Control tests (not specified)
Number of subjects: 11
Study 2309513 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefamandole
Number of subjects: 0
Study 2309513 — intervention group
Group type: COMPARATOR
Intervention: Cefazolin
Number of subjects: 0
Study 6782251 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical thio-tepa (30 mg or 60 mg) for ablation
Number of subjects: 188
Study 6782251 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical thio-tepa (30 mg or 60 mg) for prophylaxis
Number of subjects: 188
Study 6782251 — intervention group
Group type: COMPARATOR
Intervention: Control group (no thio-tepa prophylaxis)
Number of subjects: 188
Study 29799332 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialogue intervention
Number of subjects: 88
Study 29799332 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 88
Study 28486720 — intervention group
Group type: EXPERIMENTAL
Intervention: SMILE
Number of subjects: 110
Study 28486720 — intervention group
Group type: COMPARATOR
Intervention: WFG LASIK
Number of subjects: 110
Study 24195918 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic training
Number of subjects: 0
Study 24195918 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training
Number of subjects: 0
Study 24195918 — intervention group
Group type: COMPARATOR
Intervention: Balance and tone classes
Number of subjects: 0
Study 23329534 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency Coagulation (RFC)
Number of subjects: 30
Study 23329534 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Hemorrhoidal Radiocoagulation (CHR)
Number of subjects: 30
Study 20413453 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren 300 mg
Number of subjects: 18
Study 20413453 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil 240 mg/d for 8 days
Number of subjects: 18
Study 20413453 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren administered alone or in combination with verapamil
Number of subjects: 18
Study 20413453 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren and verapamil combination
Number of subjects: 18
Study 19152689 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise therapy with manual therapy
Number of subjects: 150
Study 19152689 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise therapy only
Number of subjects: 150
Study 19152689 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control
Number of subjects: 150
Study 17426180 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose oral mebendazole 500 mg
Number of subjects: 271
Study 17426180 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple dose mebendazole
Number of subjects: 271
Study 17426180 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose albendazole
Number of subjects: 271
Study 17426180 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple dose albendazole
Number of subjects: 271
Study 17426180 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 271
Study 15247138 — intervention group
Group type: EXPERIMENTAL
Intervention: Difluoromethylornithine (DFMO) at a dosage of 0.5 g/m(2)/d for approximately 13 weeks (cumulative dose of 45 g/m(2))
Number of subjects: 1
Study 11465013 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitors (SSRIs)
Number of subjects: 0
Study 11465013 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine (an SSRI)
Number of subjects: 0
Study 11465013 — intervention group
Group type: COMPARATOR
Intervention: SSRIs (general)
Number of subjects: 0
Study 11465013 — intervention group
Group type: COMPARATOR
Intervention: TCAs
Number of subjects: 0
Study 9571599 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal 17 beta‐estradiol at a dose of 50 micrograms per 24 h for 18 days followed by 10 days of combined treatment with medroxyprogesterone acetate (MPA) 5 mg orally
Number of subjects: 60
Study 9571599 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated estrogens orally for 18 days followed by a combined treatment with MPA for 10 days
Number of subjects: 60
Study 9571599 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 7924783 — intervention group
Group type: EXPERIMENTAL
Intervention: Indwelling catheters (Insuflon) for insulin injections
Number of subjects: 16
Study 7924783 — intervention group
Group type: COMPARATOR
Intervention: Standard insulin injections (without Insuflon)
Number of subjects: 16
Study 3050858 — intervention group
Group type: EXPERIMENTAL
Intervention: Acellular pertussis vaccines
Number of subjects: 3801
Study 3050858 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3801
Study 31095127 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical exercise therapy
Number of subjects: 60
Study 31095127 — intervention group
Group type: COMPARATOR
Intervention: Conventional correction methods
Number of subjects: 60
Study 28189404 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive surgery (MIS) for TKA
Number of subjects: 66
Study 28189404 — intervention group
Group type: COMPARATOR
Intervention: Standard approach for TKA
Number of subjects: 66
Study 25148382 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic tacrolimus (Tacni)
Number of subjects: 28